Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance

* Record-High First Half Revenues of $100.2 Million, up 13% Year-over-Year; Record-High First Half Adjusted EBITDA of $25.7 Million, a 26% margin of Revenues, up 14% Year-over-Year * Record-High Second Quarter Revenues of $54.9 Million, up 23% Year-over-Year; Second Quarter Adjusted EBITDA of $14.1 Million, a 26% margin of Revenues, up 29% Year-over-Year * Net Income for the First Half was $13.4 Million, up 18% Year-over-Year; Second Quarter Net Income of $9.3 Million, up 26% Year-over-Year * Company Affirms 2026 Annual Guidance of $200 Million – $205 Million in Revenues and $50 Million – $53 Million of Adjusted EBITDA, Representing Annual Double-Digit Organic Profitable Growth * Strong Cash Generated from Operating Activities of $17.8 Million During the First Six Months of 2026, Compared to $7.5 Million During the First Six Months of 2025 * Secured a First-Time Strategic Three-Year Sales Agreement of approximately $50 Million to Supply Plasma to a Leading Biopharmaceutical Company * Company Remains Focused on Accelerating Growth Through Business Development and M&A Transactions * Conference Call and Live Webcast Today at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced financial results for the three months and six months ended June 30, 2026.